Liquid Tamiflu hits FDA shortage list; India nixes new controls on foreign pharma deals; Impax and Durect ink a deal;

@FiercePharma: Dean Hart, ex-Takeda VP sales, joins consulting firm Delta Point. Release | Follow @FiercePharma

@TracyStaton: Most-read report at FiercePharma Tuesday: Top 10 Drug Patent Losses of 2014. More from FiercePharma | Follow @TracyStaton

@EricPFierce: Put FiercePharma in your pocket. Get the mobile app for iOS or Android here, fiercepharma.com/mobile | Follow @EricPFierce

@CarlyHFierce: Welcome to our newest addition to the Fierce Life Sciences team, associate editor Emily Wasserman! You can find her at @EmilyWFierce. | Follow @CarlyHFierce

> The oral liquid form of Roche's ($RHHBY) flu fighter, Tamiflu, often used for children, is running scarce, the FDA says; supplies are expected to return to normal mid-month. Report

> India has decided against capping foreign investment in "critical" areas of the pharma industry, allowing multinational companies to continue buying controlling stakes in Indian drugmakers, subject to regulatory review. Report

> Impax Laboratories ($IPXL) and Durect ($DRRX) inked a deal to resurrect the latter's patch for shingles pain, Eladur; the companies will co-develop and commercialize the product. Release

> Chapel Hill, NC-based G1 Therapeutics recruited former Johnson & Johnson ($JNJ) executive Seth Rudnick to join its board. Report

> Methamphetamine seized in a recent Chinese drug bust was made using GlaxoSmithKline's ($GSK) popular cold medicine, Contac, officials said; GSK said it is "very concerned" by diversion of its drugs for illicit purposes. Report

Medical Device News

@FierceMedDev: India's Forus hauls in $8M for portable eye-screening device. More | Follow @FierceMedDev

@MichaelGFierce: Durect, Impax tie up for a shingles patch to last 6 times as long as Lidoderm. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: FiercePharma has gone mobile! Check out the new app here. | Follow @EmilyWFierce

@GalenMoore: Former Hologic CEO Cascella lands at rival DySIS. Story | Follow @GalenMoore

> Foundation Medicine teams up with Novartis for cancer diagnostics. Item

> ArthroCare will pay $30M to finally settle up with the feds. Story

> Analysts have high hopes for St. Jude in 2014. Article

Biotech News

@FierceBiotech: AbbVie adds a slate of $280M wagers on Seattle Genetics' "armed" antibody cancer tech. News | Follow @FierceBiotech

@JohnCFierce: Another SGLT2 drug arrives. Farxiga (dapagliflozin) from AZ. Release | Follow @JohnCFierce

@DamianFierce: Friendly reminder that there were 27 drugs approved last year and we wrote, like, 1,000 words on each. Report | Follow @DamianFierce

@EmilyMFierce: AstraZeneca has made 3 deals in past 5 days. Today with Immunocore: Story. Yesterday was Horizon: News. | Follow @EmilyMFierce

> Ironwood focuses on sales, sacrifices R&D in restructuring. More

> $25M Series B helps Blueprint Medicines pursue individualized cancer therapies. Story

> Catalyst boosted as 'breakthrough' PhIII drug clears safety hurdle. Article

Drug Delivery News

> Gene delivery method 'hijacks' tumor blood vessels. More

> How a single nanoparticle delivers two drugs separately to kill cancer cells. Story

> Durect, Impax tie up for a shingles patch to last 6 times as long as Lidoderm. Article

> Vaccine nanoparticles offer shake-and-bake field delivery. Report

> Armed with cancer drugs, white blood cells become cancer-killing sticky bombs. News

> India to require all changes in delivery to be regulated as a new drug. Item

Diagnostics News

> Metabolon names two new investors in its $15M Series E. More

> Foundation Medicine deepens its Novartis ties with new deal. News

> Maverix Biomics hauls in $6M for gene sequencing software. Item

> The market for noninvasive prenatal tests could triple by 2019, analysts say. Story

> Kindstar partners with Israeli BioView to bring lung cancer Dx to Asia. Report

> SRI bags $4.5M NIH contract to set up metabolomics outpost. Article

And Finally... Developing shingles, a painful skin condition caused by the chickenpox virus, can increase one's risk of heart attack. Report